Skip to main content
Clinical Trials/JPRN-jRCTs051200048
JPRN-jRCTs051200048
Recruiting
Phase 2

Phase II study of adjuvant chemotherapy with S-1 for cStage II and III thoracic esophageal cancer following neoadjuvant chemotherapy and curative esophagectomy - SUNSHINE Trial

Kitadani Junya0 sites27 target enrollmentAugust 26, 2020

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Kitadani Junya
Enrollment
27
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 26, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kitadani Junya

Eligibility Criteria

Inclusion Criteria

  • (1\) Histologic confirmation of squamous cell carcinoma or adenocarcinoma
  • orbasaloid carcinoma by endoscopic biopsy
  • (2\) Carcinoma are all localized in the thoracic esophagus
  • (3\) TMN clinical stage II, III
  • (4\) 20 years and older, under 80 years old
  • (5\) ECOG performance status 0\-1
  • (6\) Patients who received more than 2 courses of docetaxel \+ cisplatin \+
  • S\-1 (DCS therapy) as preoperative adjuvant chemotherapy
  • (7\) Patients who underwent curative esophagectomy (R0\) with any surgical approach
  • (8\) Patients who can start adjuvant chemotherapy

Exclusion Criteria

  • 1\)Patients with concurrent other primary cancer requiring treatment
  • 2\)Patients whose recurrence has already been confirmed at the time of registration
  • 3\)Pregnancy, possibly pregnant, or breast feeding
  • 4\)Patients with psychosis or psychiatric symptoms
  • 5\)Patients requiring systemic administration of steroids
  • 6\)Positive HBs antigen
  • 7\)Severe hypersensitivity to S\-1
  • 8\)Under treatment with flucytosine, phenytoin or warfarin
  • 9\)Complication with interstitial pneumonia, pulmonary fibrosis, or severe emphysema
  • 10\)Dementia

Outcomes

Primary Outcomes

Not specified

Similar Trials